Introduction
Gilles de la Tourette syndrome (GTS) 1 (OMIM 137580) is a complex neuropsychiatric disorder characterized by a large range and variable number of unwanted repetitive simple or complex motor and vocal tics that start in childhood and follow a waxing and waning course. [2] [3] [4] [5] [6] Population prevalence of tics is around 5%, 7 of GTS between 2-8 per 1000 men and 0.1-4 per 1000 women. 6, 8, 9 Family studies reveal increased risks of tics, GTS, and obsessive compulsive disorder (OCD) among relatives of GTS probands, with more OCD among their female (up to 15%), and more tics (up to 20%) and GTS (up to 17%) among their male relatives, independently of whether the proband with GTS is having co-morbid OCD. 10, 11 Although there is evidence for a genetic basis for GTS, 11, 12 there appears to be substantial phenotypic as well as allelic heterogeneity. Moreover, environmental factors interact with genetic ones, thus influencing severity and course of the syndrome. 13 As large-scale epidemiological twin studies have not been performed in GTS, the proportion of genetic versus environmental influences has not been established. 14 The largest scale twin study in GTS to date showed concordances for GTS to be 53 and 8% for monozygotic (MZ) (n pairs = 30) and dizygotic (DZ) pairs (n = 13), respectively. 15 Concordances increased to 77 and 23% for MZ and DZ pairs when diagnostic criteria were relaxed to include any tics. These concordance rates suggest an autosomal dominant mode of inheritance, and genetic as well as environmental factors to be of importance.
Historically, cytogenetic studies were among the first done to study chromosomal aberrations possibly involved in GTS. These yielded several candidate regions, however none of the involved breakpoints has yet led to a final breakthrough. Candidate regions or genes that have been indicated by chromosomal aberrations include chromosomes 9p, 16 7q22, 18q22, 17 8q22, 18 a de novo duplication indicating the IMMP2L gene at 7q31, 19 disruption of the CNTNAP2 gene at chromosome 7q35-36 in three affected individuals in one family, 20 a chromosome 18q21-22 inversion, 21 and a translocation breakpoint at 8q. 22 Finally, a very recent study in a child with GTS has identified a de novo chromosome 13q inversion, indicating the Slit and Trk-like family member 1 (SLITRK1) geneinvolved in dendritic growth -to be a candidate gene.
23 SLITRK1, one of three genes mapping within 500 kb of the breakpoints, was considered a candidate gene because of a possible gene expression alteration due to a position effect. Subsequently, SLITRK1 was sequenced in 174 unrelated GTS probands. One single-base deletion in the coding region leading to a frameshift mutation and two identical single-base changes in the 3 0 UTR were identified in three different patients. These changes were considered to be in the binding site for micro-RNA hsa-miR-189. Both SLITRK1 and mRNA hsa 189 are brain expressed, in regions known to be involved in GTS. Although this is an encouraging finding, these variants were only found in 1% of the tested GTS patients, and need further replication. We decided to sequence the SLITRK1 gene in a number of GTS patients from the family described in this paper.
A second approach to look for responsible genes is genetic studies, including linkage and association studies. Segregation analyses have in the course of time pointed into the direction of a complex mode of transmission, 24 with more than one gene being involved. Linkage and association studies have suggested the involvement of several chromosomal regions including 4q, 8p, 25 26 described association in an Afrikaner population and linkage in a large French Canadian family to the same marker D11S1377, respectively. However none of the described linkage or association studies has indicated an obvious candidate gene.
One of the main problems in complex disorders including GTS is the definition of the phenotype that is characterized by a wide range of symptoms and variation in symptom severity. In addition, the symptoms can wax and wane in individual patients over the course of days, weeks, months, or even years. Moreover, many patients can effectively suppress or cover up their symptoms in the consultation room of the physician. Further, both sex and epigenetic factors seem to influence symptom characteristics and severity. Finally, there appears to be variation in disease penetrance and an influence of assortative mating on symptom severity. All these factors contribute to the large variability of the phenotype.
Age of onset lies between 2 and 15 years (mean age is 7 years), and in many cases symptoms can diminish significantly in the mid-to late-teen years and subsequently co-morbid conditions may complicate the clinical picture of the disease. Thus when persons are enrolled in a genetic study as adult, clinicians are partly dependent on retrospective interviews or chart reviews, which hamper reliability of symptom detection.
This article describes the clinical evaluation of patients and family members in a large Dutch GTS pedigree, and subsequent linkage analysis of this pedigree and the decisions encountered that one has to take with respect to phenotyping combined with the linkage analyses.
Materials and methods

Subjects
The family was recruited at an outpatient child psychiatric clinic, where psychiatric evaluation had been requested by parents on the presence of tics and obsessive-compulsive symptoms (OC symptoms) in all four of their children. Subsequently, all family members were invited to participate in a family study and written informed consent was obtained from all family members separately. In children under 16 years of age, informed consent was obtained from both parents on the evaluation of their children. A total of 27 subjects were evaluated on the presence of tics and OC symptoms according to DSM-IV criteria, 5 and with the aide of the Yale Global Tic Symptom and Severity scales, 32 the Yale-Brown ObsessiveCompulsive Scale (symptom checklist and severity scales), 33, 34 and additional ratings on attention deficit hyperactivity disorder (ADHD), according to standards adopted from the Tourette Syndrome Association genetic International Consortium. 35 Diagnoses were subsequently established with the aid of the Diagnostic Confidence Index, using the subdivisions possible, probable, and definite. 36 Patients and their family members were either investigated at the outpatient services or in the home situation, depending on their willingness to visit the services.
Furthermore, blood was obtained through standard venapuncture into ethylene diamine tetra acetate (EDTA) tubes, and, in case of refusal of blood sampling, buccal swabs were obtained.
Genotyping
Genomic DNA was isolated from peripheral leukocytes, using a PUREGENE DNA Purification Kit (Gentra Systems; Plymouth, USA). For the genome scan, 382 microsatelite markers from the ABI prism set MD 10 (version 2.5) were used with a mean spacing of 10 cM. Additional markers for fine mapping were newly developed by us as described before. 37 Markers were amplified using 25 ng genomic DNA in 7.5 ml PCR reactions containing 1 Â PCR Gold Buffer, 2.5 mM MgCl 2 , 10mM primer pair mix, and 0.4 U AmpliTaq Gold DNA polymerase (Applied Biosystems, Nieuwerkerk a/d Yssel, The Netherlands). Amplification conditions were 10 min at 951C followed by 35 cycles of 30 s at 951C, 30 s at 551C, and 1 min 30 s at 721C. After a final extension for 5 min at 721C, PCR products were pooled in panels and loaded on an ABI 3100 automated sequencer. Data were analyzed using Gene Mapper Version 2.1 software (Applied Biosystems).
Simulation and linkage analysis
Genotyping was done on all available 27 family members. In the simulation and linkage analysis only one of the identical twins was included.
A two-point simulation study was performed using SLINK and MSIM programs; 38, 39 two-point LOD scores were computed using the MLINK program of the FastLink package version 5.1. [40] [41] [42] [43] Multipoint linkage analysis was performed using SimWalk2 v. 2.91. 44 The pedigree of the shown family makes a strong case for an autosomal dominant model with variable penetrance. Therefore, LOD scores were calculated assuming GTS to be an autosomal dominant disorder, in line with Curtis et al. with 81% penetrance for males and 31% for females, and a phenocopy rate for males of 0.005 and for females of 0.003 with GTS. 45 For chronic multiple tic syndrome (CMT), a penetrance of 90% was assumed for males and of 56% for females, with a phenocopy rate for males of 0.01 and for females of 0.06. A gene frequency of 0.01 was assumed. 45 Subjects within the diagnostic categories of GTS and CMT (intermediate diagnostic model) were used in the linkage calculations (Table 1) . 46, 47 We have chosen to apply strict criteria as to who is affected or unaffected. The advantage of this conservative approach is that it avoids an overestimation of the LOD score(s). Therefore, subjects with a diagnosis of probable or possible symptoms were included as unknown, as well as children under the age of 18 years without symptoms, since according to DSM-IV classification criteria (APA, 1994), GTS can occur until the age of 18 years. 4 Recombination frequencies were assumed to be equal between males and females. Equal allele frequencies were used in the calculations. Changing allele frequencies did not significantly alter LOD scores. Haplotypes were constructed manually, based on the minimal number of recombinations.
To check for mendelian inheritance, inheritance check was done for all family members, using the program Pedcheck. 48 Mutation analysis on SLITRK1 gene Amplification reactions were performed in 22 ml containing 1 Â Invitrogen PCR buffer, 1.5 mM MgCl 2 , 0.01% W-1, 250 mM of each dNTP, 1 mM forward primer, 1 mM reverse primer, 0.75 U of Platinum Taq DNA polymerase (Invitrogen) and 25 ng genomic DNA; DNA Cycle conditions: 7 min 30 s 951C, 10 cycles of 30 s denaturation 941C annealing 681C minus 11C per cycle, 1 min extension 721C, followed by 25 cycles of 30 s denaturation 941C annealing 581C 1 min extension 721C final extension 5 min 721C
Primer sequences were used as described by Abelson et al.;
23 Additionally, the following primer sets were used to amplify SLITRK1 sequences.
Templates for the Direct Sequencing reactions were cleaned from dNTP's and primers using 1 ml ExoSAP-IT (USB) during 30 min at 371C followed by a 15 min inactivation step at 801C. Direct sequencing of both strands was performed using Big Dye Terminator chemistry ver.3.1 (Applied Biosystems) as recommended by the manufacturer. Fragments were loaded on an ABI3100 automated sequencer and analyzed with DNA Sequencing Analysis (ver.3.7) and SeqScape (ver.2.1) software (Applied Biosystems).
Real-time PCR
Relative copy numbers for both SLITRK1 alleles were determined using 25 ng of patient/control DNA in a 25 ml reaction containing 1 Â iTaq SYBR Green Supermix with ROX (Bio-Rad) and 200 nM of each primer. Cycle conditions on a 7300 Real Time PCR System (Applied Biosystems): 10 min 951C initial denaturation followed by 40 cycles 15 s denaturation; annealing/extention and data collection 1 min 601C. Data were analyzed using 7300 System SDS Software RQ Study Application V 1.2.3 (Applied Biosystems). Primer sequences used
Results
The pedigree consists of 31 living persons, shown in Figure 1 . Of these, 27 were available for evaluation of their clinical status and for obtaining a blood sample. In Table 1 the clinical features of each patient are described, the final diagnoses given in the last column were used in the linkage analysis.
Genetic and molecular analysis Simulations using SLINK and MSIM suggested an average LOD score of 1.75 at y = 0, demonstrating that the family had enough statistical power to detect at least suggestive evidence for linkage. 49 For the simulation and actual linkage analysis the same genetic parameters have been used (Materials and methods).
A genome-wide can was performed using the 382 polymorphic microsatellite marker set (ABI-prism). Two-point linkage analysis resulted in three chromosomal areas with highest positive LOD scores above 2 for at least one marker, see Table 2 . For two regions, additional markers were tested and multipoint linkage analysis was performed for all three regions. This resulted in three separate linkage peaks on chromosomes 3q, 9q, and 13q, Figure 2a- Abbreviations: GTS = Gilles de la Tourette syndrome; CMT = chronic multiple tic syndrome; CVT = chronic vocal tic syndrome; NOS = not otherwise described; OC symptoms = obsessive-compulsive symptoms; ADHD = attention deficit hyperactivity disorder.
1 and 2, respectively. Haplotype analysis on all three regions is shown in Figure 3 . The proximal boundary for the chromosome 3q region is determined by a recombination event in individual 3 between D3S1262 and D3S2436. The distal boundary is determined by a recombination event in individual 15 between D3S240 and D3S1265, assuming that the phenotype of possible tic disorder (not otherwise described, NOS) belongs to the Tourette spectrum. Child 16, son of individual 15, has inherited the same haplotype and is diagnosed with definite CMT. The maximum candidate gene region stretches from D3S1262 to D3S1265, has a size of 21 cM (9.4 Mb) and contains 64 genes. The minimum region stretches from D3S2436 to D3S240, has a size of 15.5 cM (7 Mb) and contains 31 genes. We selected four genes from the minimal region, Fibroblast growth factor 12 (Fgf12), 50 Hairy and enhancer of split 1 (Hes1),
51
Loc151963 and Urotensin 2 domain containing (Uts2b/Urp), 52 based on their expression in brain/ nervous system and sequenced the open reading frame. No mutations or unknown SNPs were detected.
Although the multipoint LOD score excluded the region on chromosome 13 as a candidate region when using both GTS and CMT in the linkage calculations, all six patients with definite GTS carry the same allele for marker D13S170, the marker closely associated with the SLITRK1 gene. This indicates that using a stricter selection of GTS patients only (narrow model) 46, 47 in the linkage analysis, the linkage peak on chromosome 13 would still be of interest. We have, therefore, sequenced the SLITRK1 gene in two of the affected individuals (patients nos. 2) compared to control DNA.
Discussion
The findings described in this paper indicate suggestive linkage on chromosome 3q for a large Dutch pedigree, segregating Gilles de la Tourette syndrome and tics. Using two-point linkage analysis, initially three regions (on chromosomes 3q, 9q, and 13q) were of interest; however, with multipoint linkage analysis, the LOD scores for chromosomes 9 and 13 drop below 1 and 2, respectively. The overall LOD scores for the distal markers on chromosome 3q, however, increased, with the highest LOD score of 2.55 for marker D3S1311. Haplotype analysis for the three regions is given in Figure 3a -c. This family can be considered as an informative family, with multiple family members being affected, although overall they are displaying mild symptoms. Mild symptoms appear to be more heritable than severe symptoms, as is described for families containing severely affected probands. 53 However, there are still several unresolved issues regarding the inheritance in this family. We have used subjects with the diagnostic categories of GTS and CMT (intermediate diagnostic model) 47 in the linkage calculations. Ten such persons are described in this family.
It is clear that on chromosome 9 of these 10 patients, individual 29 (def. GTS) does not carry the assumed affected haplotype, and reversely, one healthy person, no. 41, does, Figure 3b . This is clearly reflected in the low LOD scores for chromosome 9, see Table 2 . On chromosome 13, individual 19 (def. CMT) does not carry the assumed affected haplotype. However, in this situation, no healthy individual carries the affected haplotype, Figure 3c , which is reflected in a higher though not significant LOD score (Table 3) .
The assumed affected haplotype on chromosome 3q accounts for all individuals with the clinical description of GTS and CMT in the pedigree, Figure 3a . The affected haplotype for individual 18 can be explained by the fact that the timepoint of diagnosis is below the age of 18 years. In addition, individual 31, a probable chronic vocal tic syndrome (CVT), also carries the affected haplotype. The family branch consisting of individuals 33, 35, and 36 are diagnosed as probable CMT þ CVT 33 and possible CMT. 35, 36 However, these individuals do not carry the affected haplotype, and thus they possibly could be considered as phenocopies. And the same is true for individual 17 (possible CMT). Aditionally, it is possible that other genetic determinants are present beyond the 3q locus. Reversely, individual 41, who was interviewed at the age of 77 years and said to have never had any symptoms, carries the assumed affected haplotype. Interestingly, of this person, the interviewer (JB) had noted that tic history was not very reliable as the person was old and minimally motivated to cooperate in the study, which might have elicited false-negative responses to the tic questions.
Although the multipoint LOD score excluded the region on chromosome 13q as a candidate region, we have sequenced the SLITRK1 gene, because in all six patients with definite GTS, the same allele for the closely associated marker D13S170 was present, but no mutation was found. However, mutations in SLITRK1 in GTS patients are rare up till now. 23 These results immediately pinpoint the difficulties in diagnosis used for linkage analysis in Tourette syndrome. Most studies of psychiatric illness, regardless of whether they are aimed at unraveling the etiology, biology, and phenomenology on the one hand or treatment effects on the other, rely for their inclusion criteria on patient selection by clinicians. 54 Therefore, this clinician-determined patient selection is of core importance to the success of research efforts. Acknowledgement of the importance of valid and reliable diagnoses has led to the introduction of DSM, and to the development of questionnaires and rating scales to improve consensus across clinicians across countries. Yet, the inclusion of patients in studies is still based on the combination of assumptions at a nosological level and consensus among clinicians with respect to presence (and severity) of symptoms. This first stage of patient selection basically entails the most vulnerable step in research efforts. 54 There- fore, it appears to be crucial in future endeavors on GTS to search for more stable heritable endophenotypes of GTS, derived from neuro-imaging, neuropsychological, and eye movement studies 55 in order to be more successful in unraveling the genetic background of the disorder. Further, identification of more homogeneous phenotypes by using factoranalysed quantitative symptom dimensions might prove to be fruitful. 56, 57 The future will learn which strategy will be the most helpful in unraveling the genetics of GTS.
